Literature DB >> 23281467

Mucopolysaccharide disorders in orthopaedic surgery.

Klane K White1, Ted Sousa.   

Abstract

The mucopolysaccharidoses (MPSs) are a family of disorders characterized by the accumulation of glycosaminoglycans, which is caused by enzyme deficiencies in the lysosomal metabolism of these normal cellular byproducts. Skeletal abnormalities are early and prominent features of MPS, and the orthopaedic surgeon is often the first healthcare provider to raise suspicion for this diagnosis. Recently developed medical therapies for the management of MPS (ie, hematopoietic stem cell transplantation, intravenous enzyme replacement therapy) have led to increased lifespan but have not had much effect on the development of skeletal deformities. Patients must be monitored carefully and treated surgically as necessary. Conditions that may require surgical management include cervical spine and atlantoaxial instability, gibbus deformity, hip dysplasia and osteonecrosis, genu valgum, and carpal tunnel syndrome. The orthopaedic surgeon should have a basic understanding of MPS and of the clinical presentation, musculoskeletal abnormalities, and radiographic findings associated with this group of disorders.

Entities:  

Mesh:

Year:  2013        PMID: 23281467     DOI: 10.5435/JAAOS-21-01-12

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  12 in total

1.  Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs.

Authors:  Sun H Peck; Philip J M O'Donnell; Jennifer L Kang; Neil R Malhotra; George R Dodge; Maurizio Pacifici; Eileen M Shore; Mark E Haskins; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2015-09-26       Impact factor: 4.797

Review 2.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

3.  Spinal cord compression in patients with mucopolysaccharidosis.

Authors:  Tobias Pantel; Mona Lindschau; Andreas M Luebke; Philip Kunkel; Marc Dreimann; Nicole Muschol; Sven O Eicker
Journal:  Eur Spine J       Date:  2022-03-10       Impact factor: 2.721

Review 4.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

5.  The Complexity of Pain Management in Children Affected by Mucopolysaccharidoses.

Authors:  Sabrina Congedi; Chiara Di Pede; Maurizio Scarpa; Angelica Rampazzo; Franca Benini
Journal:  Case Rep Pediatr       Date:  2017-04-03

6.  Pathophysiology of Hip Disorders in Patients with Mucopolysaccharidosis IVA.

Authors:  Zhigang Wang; Yunlan Xu; Enze Jiang; Jianmin Wang; Shunji Tomatsu; Kaiying Shen
Journal:  Diagnostics (Basel)       Date:  2020-04-29

7.  Best practice guidelines for management of spinal disorders in skeletal dysplasia.

Authors:  Klane K White; Michael B Bober; Tae-Joon Cho; Michael J Goldberg; Julie Hoover-Fong; Melita Irving; Shawn E Kamps; William G Mackenzie; Cathleen Raggio; Samantha A Spencer; Viviana Bompadre; Ravi Savarirayan
Journal:  Orphanet J Rare Dis       Date:  2020-06-24       Impact factor: 4.123

8.  Does orthopaedic surgery improve quality of life and function in patients with mucopolysaccharidoses?

Authors:  N Williams; D Challoumas; D M Eastwood
Journal:  J Child Orthop       Date:  2017-08-01       Impact factor: 1.548

9.  A Unique Case of Cervical Myelopathy in an Adult Patient with Scheie Syndrome.

Authors:  Farzam Vazifehdan; Vasilios G Karantzoulis; Robert Ebner; Vasilios G Igoumenou
Journal:  J Orthop Case Rep       Date:  2017 Nov-Dec

Review 10.  Pain in Mucopolysaccharidoses: Analysis of the Problem and Possible Treatments.

Authors:  Sabrina Congedi; Marcello Orzalesi; Chiara Di Pede; Franca Benini
Journal:  Int J Mol Sci       Date:  2018-10-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.